DEVELOPMENT OF EXTENDED RELEASE GALANTAMINE CAPSULES

Masiha Afrin*, Suresh Kumar P., Jagannath Patro V., Sunitha C. H. and Vanitha S.

ABSTRACT

The objective of this study was to design oral extended release tablets of Galantamine Hydrobromide which can be used to moderate or delay the manifestation of Alzheimer’s disease HPC HXF as the retardant polymer and to study the effect of various formulation factors such as polymer proportion, concentration of glidant, lubricant and their impact on the formulation. The tablets were prepared by the direct compression method. The formulated tablets were also characterized by physical and chemical parameters. The powder blend showed satisfactory flow properties, compressibility, and drug content. In vitro release studies were performed using US Pharmacopeia type II apparatus (Paddle method) in 900 ml of pH 6.8 phosphate buffer, 0.1 N HCl and pH 4.5 Acetate buffer. The total release proportions of galantamine hydro bromide from extended release tablets of optimized formula of F15 reached higher than 85 % within 12 hrs in all media.

Keywords: Galantamine Hydrobromide, Alzheimer’s disease, HPC HXF Polymer.